The former CEO and CFO of Embattled Canadian pharmaceutical company Valeant, a core holding of Bill Ackman's hedge fund Pershing Square Capital Management, are reportedly the focus of U.S. prosecutors as they explore whether to bring a fraud case against the drugmaker.